Phylogica says study shows Phylomers' suitability for stroke, trauma treatment

By Lisa Kerner

Charlotte, N.C., July 31 - Phylogica said international laboratory tests have confirmed that its new Phylomer stroke drugs, PYC35S and PYC36S, have suitable stability properties to function as stroke therapies.

Phylomers are small fragments of protein that block inappropriate interactions of proteins that cause disease.

The half lives in animals of the Phylomers were five-to16-fold better than the leading emergency stroke therapy, tissue plasminogen activator administered intravenously, according to the company.

"What these data tell us is that these Phylomer drugs are very stable in fresh human plasma and will last in the body for the optimal amount of time needed to be an effective treatment for stroke," chief executive officer Stewart Washer said in a news release.

Phylomers could be effective in stopping the large-scale death of surrounding brain cells that occurs following a stroke and major brain injury, officials said.

Further animal model tests are planned in collaboration with UTAS Innovation Ltd., the commercial arm of the University of Tasmania and the Australian Neuromuscular Research Institute.

Phylogica is a drug discovery company based in Perth, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.